SABS – sab biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) [Yahoo! Finance]
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
SAB Biotherapeutics, Inc. (NASDAQ: SABS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $11.00 price target on the stock.
Form 10-Q SAB Biotherapeutics, For: Sep 30
Form 4 SAB Biotherapeutics, For: Nov 01 Filed by: Ellias Helen K.
Form 8-K SAB Biotherapeutics, For: Sep 09
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.